RT Journal Article
SR Electronic
T1 Early prognostication of overall survival for pediatric diffuse midline gliomas using MRI radiomics and machine learning: a two-center study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.01.23297935
DO 10.1101/2023.11.01.23297935
A1 Liu, Xinyang
A1 Jiang, Zhifan
A1 Roth, Holger R.
A1 Anwar, Syed Muhammad
A1 Bonner, Erin R.
A1 Mahtabfar, Aria
A1 Packer, Roger J.
A1 Kazerooni, Anahita Fathi
A1 Bornhorst, Miriam
A1 Linguraru, Marius George
YR 2024
UL http://medrxiv.org/content/early/2024/01/03/2023.11.01.23297935.abstract
AB Background Diffuse midline gliomas (DMG) are aggressive pediatric brain tumors that are diagnosed and monitored through MRI. We developed an automatic pipeline to segment subregions of DMG and select radiomic features that predict patient overall survival (OS).Methods We acquired diagnostic and post-radiation therapy (RT) multisequence MRI (T1, T1ce, T2, T2 FLAIR) and manual segmentations from two centers of 53 (internal cohort) and 16 (external cohort) DMG patients. We pretrained a deep learning model on a public adult brain tumor dataset, and finetuned it to automatically segment tumor core (TC) and whole tumor (WT) volumes. PyRadiomics and sequential feature selection were used for feature extraction and selection based on the segmented volumes. Two machine learning models were trained on our internal cohort to predict patient 1-year survival from diagnosis. One model used only diagnostic tumor features and the other used both diagnostic and post-RT features.Results For segmentation, Dice score (mean [median]±SD) was 0.91 (0.94)±0.12 and 0.74 (0.83)±0.32 for TC, and 0.88 (0.91)±0.07 and 0.86 (0.89)±0.06 for WT for internal and external cohorts, respectively. For OS prediction, accuracy was 77% and 81% at time of diagnosis, and 85% and 78% post-RT for internal and external cohorts, respectively. Homogeneous WT intensity in baseline T2 FLAIR and larger post-RT TC/WT volume ratio indicate shorter OS.Conclusions Machine learning analysis of MRI radiomics has potential to accurately and non-invasively predict which pediatric patients with DMG will survive less than one year from the time of diagnosis to provide patient stratification and guide therapy.KEY POINTSAutomatic machine learning approach accurately predicts DMG survival from MRIHomogeneous whole tumor intensity in baseline T2 FLAIR indicates worse prognosisLarger post-RT tumor core/whole tumor volume ratio indicates worse prognosisIMPORTANCE OF STUDY Studies of pediatric DMG prognostication have relied on manual tumor segmentation from MRI, which is impractical and variable in busy clinics. We present an automatic imaging tool based on machine learning to segment subregions of DMG and select radiomic features that predict overall survival. We trained and evaluated our tool on multisequence, two-center MRIs acquired at the time of diagnosis and post-radiation therapy. Our methods achieved 77-85% accuracy for DMG survival prediction. The data-driven study identified that homogeneous whole tumor intensity in baseline T2 FLAIR and larger post-therapy tumor core/whole tumor volume ratio indicates worse prognosis. Our tool can increase the utility of MRI for predicting clinical outcome, stratifying patients into risk-groups for improved therapeutic management, monitoring therapeutic response with greater accuracy, and creating opportunities to adapt treatment. This automated tool has potential to be easily incorporated in multi-institutional clinical trials to provide consistent and repeatable tumor evaluation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPartial support from the National Cancer Institute award 5UH3CA236536-04.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For this two-center retrospective study, Institutional Review Board approval was obtained at both participating institutions: Children's National Hospital, and Children's Hospital of Philadelphia through Children's Brain Tumor Network Protocol.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data included in the present work are not available for public use.